CRISPR Therapeutics
CRSP
276 hedge funds and large institutions have $2.91B invested in CRISPR Therapeutics in 2020 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 93 increasing their positions, 62 reducing their positions, and 45 closing their positions.
93% more capital invested
Capital invested by funds: $1.51B → $2.91B (+$1.4B)
50% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 62
42% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 45
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more funds holding
Funds holding: 257 → 276 (+19)
6.02% more ownership
Funds ownership: 58.44% → 64.46% (+6%)
13% less call options, than puts
Call options by funds: $76.8M | Put options by funds: $88.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$128M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$26.7M |
| 3 |
BlackRock
New York
|
+$23.3M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$21.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$17M |
| 2 |
GTP
Global Thematic Partners
New York
|
-$14.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$11.7M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$11.1M |
CRSP Hedge Fund Activity: Q2 2020 in Review
276 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2020, worth a combined $2.91B — up 93% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new CRSP positions and 45 closed out — a net gain of 19 holders — while 93 added to existing stakes and 62 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $128M. The largest seller was Morgan Stanley, cutting an estimated $17M.
- 276 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2020, up from 257 in Q1 2020.
- Funds reported $2.91B of CRISPR Therapeutics stock for Q2 2020, up 93% quarter-over-quarter.
- 64 funds opened new CRISPR Therapeutics positions in Q2 2020 and 45 closed out, a net change of +19 holders.
- The largest CRISPR Therapeutics buyer in Q2 2020 was ARK Investment Management, an estimated $128M added.
- The largest CRISPR Therapeutics seller in Q2 2020 was Morgan Stanley, an estimated $17M sold.
Based on aggregated 13F filings for Q2 2020.